USE OF ETHANOL WITH PARKINSON’S DISEASE, TO DRINK OR NOT TO DRINK

The medical note in this issue of the Parkinson Press explores the potential benefits of ethanol in Parkinson’s disease with a focus on red wine. Red wine may provide a dual benefit for Parkinson's disease. First the ethanol in wine is capable of direct stimulation of dopamine-containing nerve cells (dopaminergic neurons) in the substantia nigra. Second, as some of you may know, red wine contains resveratrol a plant product with several potential neuroprotective effects. Note that other foods such as peanuts also contain resveratrol.

Looking first at the direct effects of ethanol. Laboratory studies on the direct effect of ethanol on dopaminergic neurons has been examined. In this research, injection of ethanol into the substantia nigra of anesthetized rats caused a dose-related increase in locomotor activity once the anesthetic was removed (1). Enzymes such as catalase were evaluated in this regulation of ethanol-induced motor activity. Previously Gessa, et al. (2) found that low doses of ethanol induced a 30-80% increase in firing rate of dopaminergic neurons in experimental animals.

Focusing next on the effects of resveratrol. It is an antioxidant (4, 5), modulates inflammation (6, 7), and stimulates growth factors (8). Each of these properties is presented below for those who want to review them. The science itself is complex, but hopefully the summary paragraphs are clear.
What are the benefits of an antioxidant? By definition, “Antioxidants are man-made or natural substances that may prevent or delay some types of cell damage. Antioxidants are found in many foods, including fruits and vegetables” (3); many vitamins including Vitamin C are antioxidants.

Ono and Yamada (4) found a direct antioxidant effect of wine related phenols such as resveratrol on formation of alphasynuclein. You will recall that alphasynuclein is the protein that aggregates in dopaminergic neurons adversely affecting their function and ultimately their survival. The authors speculated that this group of molecules could play a key role in “the development of preventatives and therapeutics for LBD (Lewy Body disease) and MSA (Multiple System Atrophy) as well as Alzheimer’s disease”.

Albani, et al. (5) studied the neuroprotective effects of SIRT1, a protein that can protect against oxidation when activated. Such activation occurs with resveratrol. In these experiments cells that were growing in culture provided the experimental model, not experimental animals. The oxidative challenge for these cells was exposure to weak solutions of hydrogen peroxide or 6-hydroxydopamine, a chemical that can kill dopaminergic neurons. Ensuing detrimental effects were blocked by resveratrol through the SIRT1 pathway. In the same experiments, SIRT1 itself was unblocked by its inhibitor, sirtinol.

Why is resveratrol an anti-inflammatory agent? The inflammatory response in Parkinson’s disease is mediated by microglia. Glia are one of the non-neural cell types that are in the brain along with nerve cells. Proliferation of glial cells occurs after toxic insults to nerve cells in a way analogous to proliferation of scar forming cells outside of the brain following cuts and abrasions of the skin.

Zhang et al (6) examined the mechanisms underlying resveratrol-mediated neuroprotection in rat midbrain neuron-glia cultures. This region of the rat midbrain has dopamine neurons and provides a relevant model for Parkinson’s disease. Using this model, his group exposed dopamine nerve cells in culture to lipopolysaccharide, a molecule that triggers microglial proliferation and an accompanying proinflammatory factor release. Resveratrol inhibited the microglial cell formation and blocked the toxic effects of lipopolysaccharide. Biochemical details of that inhibition are provided in the report and beyond the scope of this news article.

Additional experimental work on the modulation of microglial proliferation by resveratrol was reported by Gordon et al. (7). These scientists also examined the positive modulation of apoptosis, perhaps the topic of a subsequent newsletter, by resveratrol.

Additionally, resveratrol stimulates the production and release of growth factors. You may recall that neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) are important for the development, maintenance and survival of neurons including dopaminergic neurons in the substantia nigra. Astroglia, another cell type in the brain are a source of neurotrophic factors. Zhang et al. (8) evaluated the possibility that resveratrol might stimulate the production and release of neurotrophic factors from astroglial enriched cultures. After cell cultures were exposed to low concentrations of resveratrol for 12–48 hours, BDNF and GDNF were measured in the culture medium. Following 24 hours of resveratrol exposure, the production of BDNF was increased five-fold over control levels and remained high 36 hours later. Meanwhile, the production of GDNF was initially increased by up to four-fold in 24 hours after resveratrol treatment and continued to increase to six-fold at 36 hours. The level remained high for 48 hours.

Ethanol and Multiple Sclerosis. It is notable that ethanol may be beneficial for other Neurological diseases such as MS. In January 2006, Hedstrom et al. (8) reported the results from their analysis
of two epidemiological studies. They found a dose-dependent, inverse association between alcohol consumption and risk of developing MS that was statistically significant in both sexes.

Conclusion. This report has briefly reviewed evidence for a direct stimulatory effect of ethanol on dopaminergic neurons as well as potential neuroprotective effects of resveratrol found in wine and other foods. These neuroprotective properties include antioxidation (4, 5), anti-inflammatory modulation (6, 7), and stimulation of production of growth factors (8). So enjoy a glass of red wine and don’t let all this information about resveratrol spoil its magic for you. You may also purchase resveratrol in a capsule form at most health food stores.

REFERENCES


Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol. Published online January 06, 2014
Contact Information-Disclaimer

APDA Dedicated Veterans Information and Referral Center
975 Kirman Avenue
Reno, NV 89502-0993
Telephone: 775-328-1715
Toll Free: 888-838-6256 ext 1715
Fax: 775-328-1816
Internet Site: www.reno.va.gov/parkinsons/parkinsons.asp
Intranet Site: www.va.reno.va.gov/parkinsons/parkinsons.asp
Email: Susan.Gulas@va.gov

Coordinator/Editor: Susan Gulas, RN, MSN
Medical Director: John Peacock, MD, PhD

APDA National Office
135 Parkinson Avenue
Staten Island, NY 10305-1425
Fax: 1-718-981-4399   Telephone: 718-981-8001   Toll Free: 800-223-2732
Website: www.apdaparkinson.org

Disclaimer:
The material in this newsletter is presented solely for the information of the reader. It is not intended for treatment purposes, but rather for discussion with the patient’s physician.

Permission is granted to reprint any article in this newsletter provided that proper credit is given to the author and source: APDA Information and Referral Center, Reno, Nevada.

Veteran Update

Veterans Crisis Line:

If you are in crisis, or know a veteran who is, telephone the Veterans Crisis Line toll-free 24/7/365 at 1-800-273-8255 and press 1, or text 838255, or visit the Veterans Crisis Line website at http://veteranscrisisline.net and chat with trained counselors (many of whom are veterans) anytime. This is also the National Suicide Prevention Lifeline for anyone in crisis.
Federal Benefits Book Updated:


New Veteran Care Options:

The new Veterans Access, Choice and Accountability Act give many veterans the option to receive non-VA health care rather than waiting for a VA appointment or traveling to a VA facility. Read about the new Veterans Choice Program and check your eligibility at VA’s Veterans Choice Program webpage at: www.va.gov/opa/choiceact/.

RESEARCH OPPORTUNITIES

If you are interested in current research regarding Parkinson’s disease, please visit one or all of the sites listed below.

Fox Trial Finder at www.foxtrialfinder.org

This is a website developed by the Michael J. Fox Foundation that helps people diagnosed with PD find personalized matches to clinical trials.

Clinical Trials at www.ClinicalTrials.gov

The U.S. National Institutes of Health developed this site to provide patients, family members and the public with current information about clinical research studies being funded by government and private industry. By searching for Parkinson's disease, you can get a listing of all clinical trials (including contact information) for Parkinson's disease being conducted in the U.S. and internationally. This site also provides information on the clinical trials process.

Center Watch at www.centerwatch.com

Center Watch is a listing service for clinical trials both industry and government funded. By searching for Parkinson's disease, you can get a listing of all clinical trials for Parkinson's disease being conducted in the U.S. and internationally. Contact information for each trial is included.
Parkinson’s disease can migrate from gut to brain, shows research: Parkinson’s disease is strongly linked to the degeneration of the brain’s movement center. In the past decade, the question of where disease begins has led researchers to a different part of the human anatomy. In 2003, the German neuropathologist Heiko Braak presented a theory suggesting that the disease begins in the gut and spreads to the brain. The idea has since, despite vocal critics, gained a lot of ground. Researchers at Lund University in Sweden now present the first direct evidence that the disease can actually migrate from the gut to the brain. To read more about this, go to the source: http://link.springer.com/article/10.1007/s00401-014-1343-6

Upcoming Educational Events

- AD/PD 2015, Alzheimer’s & Parkinson’s Disease Congress, March 18-22, 2015, Nice, France. For more information go to http://www2.kenes.com/adpd/pages/home.aspx


- XXII World Congress of Neurology, October 31-November 5, 2015 in Santiago, Chile.

- Aces Reno Fundraiser. Join us for a day at the ballpark on August 30, 2015 at 1:00pm to support Parkinson’s disease. Vouchers for tickets to the game are $12.00. Please call us at 775-328-1715 to reserve your seat and help raise funds to support research for Parkinson’s Disease.
**Northern Nevada Support Groups**

Contact information: 775-328-1715 or 888-838-6256 ext. 1715  
Website: [www.reno.va.gov/parkinsons/parkinsons.asp](http://www.reno.va.gov/parkinsons/parkinsons.asp)

<table>
<thead>
<tr>
<th>Location</th>
<th>Month</th>
<th>Day</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spanish Springs</td>
<td>January 7</td>
<td>First Wednesday</td>
<td>Susan Neeley RN</td>
<td>Caregiver Support Group</td>
</tr>
<tr>
<td></td>
<td>January 7</td>
<td></td>
<td>10:00 am</td>
<td>Lend-A-Hand</td>
</tr>
<tr>
<td></td>
<td>February 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carson City</td>
<td>January 13</td>
<td>Second Tuesday</td>
<td>Valerie Williams</td>
<td>Caregiver Support Group</td>
</tr>
<tr>
<td></td>
<td>February 10</td>
<td></td>
<td>2:00 pm</td>
<td>Memory in PD</td>
</tr>
<tr>
<td></td>
<td>March 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reno</td>
<td>January 9</td>
<td>Second Friday</td>
<td>Brian Terres Medtronic</td>
<td>Group Members</td>
</tr>
<tr>
<td></td>
<td>February 13</td>
<td></td>
<td>2:00 pm</td>
<td>DBS &amp; Duopa</td>
</tr>
<tr>
<td></td>
<td>March 13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reno</td>
<td>January 20</td>
<td>Third Tuesday</td>
<td>Dr. John Peacock</td>
<td>Update on Parkinson’s Disease</td>
</tr>
<tr>
<td></td>
<td>February 17</td>
<td></td>
<td>5:00pm</td>
<td>LSVT “Big”</td>
</tr>
<tr>
<td></td>
<td>March 17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparks</td>
<td>January 22</td>
<td>Fourth Thursday</td>
<td>Alison Shelton?</td>
<td>Sandy Wilson PT</td>
</tr>
<tr>
<td></td>
<td>February 26</td>
<td></td>
<td>2:30 pm</td>
<td>ADT</td>
</tr>
<tr>
<td></td>
<td>March 26</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Locations: Cascades of the Sierra, 275 Neighborhood way  
Carson City Senior Center, 911 Beverly Drive  
Atria at Summit Ridge, 4880 Summit Ridge Drive  
Veterans Administration Medical Center, meet at 4:50pm in the Kirman Street Lobby  
Morning Star Senior Living, 2360 Wingfield Hills Drive, Sparks, NV
<table>
<thead>
<tr>
<th>Reno</th>
<th>January 15</th>
<th>February 19</th>
<th>March 19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Third Thursday</td>
<td>Melissa Gerdes PT</td>
<td>Tracie Pistone</td>
<td>Amanda Smith/Tiffany</td>
</tr>
<tr>
<td>2:00pm</td>
<td>LSVT “Big”</td>
<td>Interim</td>
<td>Eden Hospice Care</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HomeStyle</td>
<td></td>
</tr>
<tr>
<td>Five Star Premier</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residences of Reno</td>
<td>3201 Plumas Street</td>
<td></td>
<td>Reno, NV 89509</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Elko-Las Vegas-Reno</th>
<th>January 2</th>
<th>February 6</th>
<th>March 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Friday</td>
<td>Jacob Harmon</td>
<td>Brian Terres</td>
<td>Don Vonerx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medtronic</td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>What is Alzheimer’s?</td>
<td>DBS &amp; Duopa</td>
<td>REMSA</td>
</tr>
</tbody>
</table>

University of Nevada Cooperative Extension, 4955 Energy Way, Reno, NV
University of Nevada Elko, 701 Walnut Street, Elko, NV

- Please bring your family member with Parkinson’s disease to the February 4th 2015 meeting. Dick Stoddard will present information of interest on Parkinson’s disease to the patient group. Caregivers will meet in the conference room on the first floor.